We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Metacrine

News List

Metacrine Reports Positive Results from Phase 1 Trial of MET642 for NASH americanpharmaceuticalreview
January 06, 2021
Metacrine has reported preliminary results from its Phase 1 trial of MET642, a farnesoid X receptor (FXR) agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH) and inflammatory bowel disease.
Metacrine Announces MET409 Receives FDA Fast Track Designation for NASH Treatment americanpharmaceuticalreview
August 26, 2020
Metacrine announced the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to MET409, the company’s lead farnesoid X receptor (FXR) agonist, for the treatment of non-alcoholic steatohepatitis (NASH).
Metacrine announces completion of series b financing biospectrumasia
December 08, 2017
Over the course of the past year, Metacrine has advanced its lead asset, MET409, an oral non-bile acid FXR agonist, into late stage IND-enabling studies
Metacrine Collaborates on FGF1 Variants for Glucose Lowering, Insulin Sensitivity americanpharmaceuticalreview
August 16, 2017
Metacrine has entered a collaboration with Novo Nordisk A/S to develop Fibroblast Growth Factor 1 (FGF1) variants for glucose lowering and insulin sensitization.